Liver Fat Content Measured by Magnetic Resonance Spectroscopy at 3.0 Tesla Independently Correlates with Plasminogen Activator Inhibitor-1 and Body Mass Index in Type 2 Diabetic Subjects

• Ishii Mototsugu

  Department of Diabetes and Metabolism, Iwate Medical University

• Yoshioka Yoshichika

  High Field MRI Research Institute, Iwate Medical University

• Ishida Wataru

  Department of Diabetes and Metabolism, Iwate Medical University

• Kaneko Yoshihito

  Department of Diabetes and Metabolism, Iwate Medical University

• Fujiwara Fumikado

  Department of Diabetes and Metabolism, Iwate Medical University

• Taneichi Haruhito

  Department of Diabetes and Metabolism, Iwate Medical University

• Miura Masanori

  Hanamaki Hotspring Branch Hospital, Iwate Medical University

• Toshihiro Makiko

  Department of Diabetes and Metabolism, Iwate Medical University

• Takebe Noriko

  Department of Diabetes and Metabolism, Iwate Medical University

• Iwai Masakatsu

  The First Department of Internal Medicine, Iwate Medical University

• Suzuki Kazuyuki

  The First Department of Internal Medicine, Iwate Medical University

• Satoh Jo

  Department of Diabetes and Metabolism, Iwate Medical University

抄録

We measured liver fat content by 3-Tesla magnetic resonance spectroscopy (MRS) in 34 non- to mild obese Japanese subjects with type 2 diabetes, who were not complicated with any liver diseases including clinical fatty liver (liver/spleen ratio of computed tomography [CT] < 0.9) and were not being treated with oral hypoglycemic agents, insulin, or lipid-lowering agents, and analyzed the relationship between liver fat content and body composition and plasma metabolite. The liver fat content is significantly correlated with variables relating to obesity (body mass index [BMI], body weight, fat mass, waist to hip ratio, visceral fat area, subcutaneous fat area, and serum triglyceride), insulin resistance (fasting plasma insulin and homeostasis model assessment of insulin resistance [HOMA-IR]), adipocytokines (serum plasminogen activator inhibitor-1 [PAI-1] and leptin), and serum cholinesterase, but not CT liver/spleen ratio, which is correlated only with fasting plasma glucose, BMI, and HOMA-IR. Multiple regression analysis revealed that the liver fat content is independently associated with serum PAI-1 level (p < 0.001) and BMI (p < 0.05), but not visceral fat area. MRS is a more sensitive method for quantifying liver fat content than CT in type 2 diabetic subjects with non- to mild obesity and without clinical fatty liver.

収録刊行物

• The Tohoku Journal of Experimental Medicine

  The Tohoku Journal of Experimental Medicine 206 (1), 23-30, 2005

  東北ジャーナル刊行会

キーワード

• type 2 diabetes
• fatty liver
• magnetic resonance spectroscopy
• plasminogen activator inhibitor-1
• body mass index

詳細情報

• CRID: 1390282679217418880
• NII論文ID: 130004459393
• NII論文ID: 10015467608
• NII書誌ID: AA00863920
• DOI: 10.1620/tjem.206.23
• ISSN: 13493329
• ISSN: 00408727
• PubMed: 15802872
• Web Site: http://www.jstage.jst.go.jp/article/tjem/206/1/206_1_23/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2006125826
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可